Streetbeat News

Regulatory

NRXP

NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:55 am

CLDX

Celldex Therapeutics has announced positive topline results from its Phase 2 trial of Barzolvolimab for moderate to severe chronic spontaneous urticaria refractory to antihistamines. The trial met its primary endpoint, showing a decrease in disease activity across multiple doses.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:43 am

KPRX

Kiora Pharmaceuticals has announced positive topline results from its Phase 1/2 trial, demonstrating that KIO-301 has the potential to significantly improve vision in patients with retinitis pigmentosa who have ultra-low vision or complete blindness.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:18 am

TSLA

Due to actions taken by Elon Musk, over 100 studies about X have been canceled, suspended, or changed, as reported by Reuters. This is because Musk's actions have limited access to necessary information. Tesla (TSLA) may be indirectly affected by this news.

Portfolio Pulse from Charles Gross

November 06, 2023 | 11:15 am

AMD

INTC

NVDA

The CEOs of Nvidia Corporation (NASDAQ:NVDA) and Advanced Micro Devices, Inc. (NASDAQ:AMD), both leaders in the global AI chip industry, are related as first cousins once removed. Both companies are key players in the semiconductor industry and are advancing in generative AI technology. However, they face potential challenges due to geopolitical tensions, with U.S. export controls affecting Nvidia's AI chips directed to China and AMD committing to U.S. restrictions while creating products for China.

Portfolio Pulse from Rounak Jain

November 06, 2023 | 10:50 am

EWY

KB

KORU

LPL

PKX

SSNLF

South Korean ADRs and ETFs, including EWY, KB, KORU, LPL, PKX, and SSNLF, have seen a rise in their shares following the government's decision to ban short selling through the first half of next year.

Portfolio Pulse from Charles Gross

November 06, 2023 | 10:46 am

KOD

Kodiak Sciences has announced that its Phase 3 GLOW Superiority Study of Tarcocimab Tedromer 5 mg in moderately severe to severe non-proliferative diabetic retinopathy has met its one-year primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:08 am

CRSP

Crispr Therapeutics has announced preclinical data from its investigational programs for the treatment of cardiovascular disease. The data shows that CTX310 and CTX320 led to durable reductions of ANGPTL3 protein and lipoprotein(a) levels respectively in non-human primates after a single dose. Both were well-tolerated at clinically relevant dose levels. A clinical trial has been initiated for CTX310, while CTX320 is set to enter the clinic in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 10:05 am

SPY

VGK

Russian President Vladimir Putin has announced his intention to run for re-election in March 2024, according to Reuters. This news could potentially impact the political stability in Russia and its relations with other countries.

Portfolio Pulse from Charles Gross

November 06, 2023 | 9:50 am

EWU

The U.K. Construction Purchasing Managers Index (PMI) for October was reported at 45.6, slightly higher than the previous month's 45 but lower than the estimated 46.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:44 am